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Abstract. Pneumonia is the leading cause of death in children. The objectives were to evaluate the microbiological
agents linkedwith hypoxemia in hospitalized childrenwith pneumonia fromdeveloping countries, to identify predictors of
hypoxemia, and to characterize factors associated with in-hospital mortality. A multicenter, observational study was
conducted in ﬁve hospitals, from India (Lucknow, Vadu), Madagascar (Antananarivo), Mali (Bamako), and Paraguay (San
Lorenzo). Children aged 2–60 months with radiologically conﬁrmed pneumonia were enrolled prospectively. Respiratory
and whole blood specimens were collected, identifying viruses and bacteria by real-time multiplex polymerase chain
reaction (PCR). Microbiological agents linked with hypoxemia at admission (oxygen saturation < 90%) were analyzed by
multivariate logistic regression, and factors associated with 14-day in-hospital mortality were assessed by bivariate Cox
regression. Overall, 405 pneumonia cases (3,338 hospitalization days) were analyzed; 13 patients died within 14 days of
hospitalization. Hypoxemia prevalence was 17.3%. Detection of human metapneumovirus (hMPV) and respiratory
syncytial virus (RSV) in respiratory samples was independently associated with increased risk of hypoxemia (adjusted
odds ratio [aOR] = 2.4, 95%conﬁdence interval [95%CI] = 1.0–5.8 and aOR= 2.5, 95%CI = 1.1–5.3, respectively). Lower
chest indrawing and cyanosis were predictive of hypoxemia (positive likelihood ratios = 2.3 and 2.4, respectively).
Predictors of death were Streptococcus pneumoniae detection by blood PCR (crude hazard ratio [cHR] = 4.6, 95% CI =
1.5–14.0), procalcitonin³50ng/mL (cHR=22.4, 95%CI=7.3–68.5) andhypoxemia (cHR=4.8, 95%CI=1.6–14.4). These
ﬁndings were consistent on bivariate analysis. hMPV and RSV in respiratory samples were linked with hypoxemia, and
S. pneumoniae in blood was associated with increased risk of death among hospitalized children with pneumonia in
developing countries.
INTRODUCTION
Despite reduced mortality rates in recent years, pneumonia
is the foremost cause of death from infectious diseases in
under 5-year-old children worldwide, accounting for 15% of
total deaths, mostly in developing countries.1 Hypoxemia,
frequently associated with pneumonia and a marker of dis-
ease severity, leads to 3- to 4-fold increased risk of death in
children with pneumonia.2 A Cochrane review3 has reported
that systematic hypoxemia screening with pulse oximetry and
appropriate oxygen supply are effective in preventing death
from pneumonia in children.
A large simulation study estimated that systematic
pulse oximetry may globally prevent almost 150,000
deaths from pneumonia annually.4 However, the micro-
biological agents linked with hypoxemic pneumonia
are poorly recognized. The identiﬁcation of such eti-
ological agents would serve to better target preventive
(i.e., vaccination) and curative measures (i.e., antibiotics
and antiviral drugs), reducing the global burden of
hypoxemia and pneumonia. Because of its high inci-
dence and related mortality, particular attention must
be paid to hypoxemic pneumonia in developing coun-
tries. Pulse oximetry is still rarely available in health-care
settings of developing countries.5 In the absence of oxi-
meter, hypoxemia can be detected by several clinical signs
or symptoms, including cyanosis and increased respiratory
rate. However, none is sensitive and speciﬁc enough to re-
liably detect hypoxemia.6–8 Most studies of hypoxemia in
children with pneumonia were performed in one country and
rarely investigated the relationship between hypoxemia and
microbiological results, so it would be useful to reassess
them in a more recent multicontinental investigation.2
The risk factors of death among children with pneumonia in
developing countries have already been identiﬁed,9,10 but
rarely regarding the relationship between microbiological
ﬁndings and mortality. Assessment of clinical, para-clinical,
and microbiological predictors of death would be useful to
prioritize public health campaigns. Identiﬁcation of microbio-
logical agents associatedwith death and/or hypoxemiawould
be useful to better focus therapeutic measures. Indeed, hyp-
oxemic pneumonia can be treated with oxygen in conjunction
with other measures, whereas non-hypoxemic pneumonia
with poor vital prognosis might need other regimens, such as
antibiotics/antivirals or intensive care.
The objectives of the present study are to assess the
microbiological agents linked to hypoxemia in hospitalized
children with pneumonia in developing countries, to identify
clinical and para-clinical predictors of hypoxemia and to
pinpoint factors associated with death within 2 weeks after
admission.
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MATERIALS AND METHODS
Study sites and design. Findings from a prospective,
hospital-based, multicenter, longitudinal study, conducted at
ﬁve sites in four countries located on three continents, were
analyzed: Lucknow and Vadu in India, Antananarivo in
Madagascar, Bamako in Mali, and San Lorenzo in Paraguay.
The participating sites are members of the GABRIEL (Global
Approach to Biological Research, Infectious Diseases and
Epidemics in Low-Income Countries) Network established by
Fondation Me´rieux.11 The study protocol and sites are de-
scribed elsewhere.12 Pneumonia cases from the original
case–control study were followed up during hospital stay and
constituted the analyzed cohort.
The study population comprised children aged between 2
and 60 months, complying with protocol deﬁnitions and in-
clusion criteria. Eligible patients were identiﬁed by study cli-
nicians at each participating site. All consecutive patients
hospitalized in pediatric departments, who were eligible for
study entry, were enrolled during each season (dry and rainy)
for at least a 1-year period. The study aimed at obtaining an
equal number of individuals in each season at each study site.
Incident cases were deﬁned as hospitalized children aged
2–60 months, with clinical features of pneumonia, as de-
scribed latter, radiological conﬁrmation of pneumonia on
chest X-ray as per World Health Organization (WHO) guide-
lines,13 and informed consent statement signed by the child-
ren’s parents or legal guardian. Wheezing at auscultation was
initially an exclusion criterion, but was amended because it
slowed the inclusion process. Thus, it was ﬁnally decided to
include children presenting pneumonia with or without
“wheezing.”
The present study selectively comprised sites with better
quality data on oxygen saturation (SO2) at admission,
mortality among pneumonia cases, and documented re-
cording of patient follow-up during hospitalization. Main
characteristics were compared by site, and multivariate
analysis accounted for heterogeneity of sites regarding
observed or non-observed potential confounding factors.
Patients with missing data on follow-up, SO2 measure-
ment, and vital status at discharge were excluded (N = 59).
Excluded patients did not differ from those analyzed for
gender and weight-for-height Z score, but were older
(P = 0.03).
Deﬁnition of pneumonia. Pneumonia cases were deﬁned
by the following criteria:
• Cough and/or dyspnea.
• Tachypnea, as delineated by the WHO (in children
2–12 months of age: breathing rate ³ 50 cycles per minute;
in children 12–59months of age: breathing rate ³ 40 cycles
per minute).14
• First symptoms appearing within the last 14 days.
• Radiological conﬁrmation of pneumonia as per WHO
guidelines, including primary endpoint pneumonia or other
inﬁltrates.13
Data sources and quality control. Data quality was moni-
tored and evaluated by each site and by the Emerging Patho-
gens Laboratory (Lyon, France) for pooled data analysis.
Demographic characteristics, underlying diseases, medical
history, clinical examination at enrollment, therapeutics, vac-
cinations, and outcomes were recorded prospectively for each
patient on a standardized paper form. Each potential error was
discussed with local investigators, and a ﬁnal ruling was ap-
plied.Theprincipal investigator at eachsitewas informedabout
quality assessments and was involved in their resolution.
Hypoxemia was deﬁned as SO2 < 90%, according to WHO
recommendations.15SO2wasmeasuredat hospital admission,
before the administration of oxygen or other therapeutics. Vital
status was recorded until patient discharge.
Biological samples. Samples were collected in the ﬁrst
48hoursofpatient hospitalization.Nasal swabs/aspirates,whole
blood, and pleural effusions (in case of pleurisy) were sampled
from all patients. Urine was collected at patient admission to
ascertain history of antibiotic use. Biological samples were
taken before the in-hospital administration of antibiotics.
Whole blood allowed complete blood count and culture, with
real-timemultiplex polymerase chain reaction (RT-PCR) assay
for the identiﬁcation of Staphylococcus aureus, Streptococ-
cus pneumoniae, and Haemophilus inﬂuenzae type B. C re-
active protein (CRP) andprocalcitonin (PCT)were quantiﬁed in
serum. Respiratory specimens permitted the identiﬁcation of
viruses and bacteria by RT-PCR assay with a panel of 19
viruses and ﬁve bacteria (Fast-track Diagnostic respiratory
pathogens 21 plus, Fast-track diagnostic, Esch-sur-Alzette,
Luxemburg), namely: inﬂuenza virus A, inﬂuenza virus
A/H1N1, inﬂuenza virus B, coronavirus 229E, coronavirus
OC43, coronavirus NL63, coronavirus HKU1, human para-
inﬂuenza virus 1, 2, 3, and 4, human metapneumoviruses
(hMPV) A and B, rhinovirus, respiratory syncytial virus (RSV) A
and B, adenovirus, enterovirus, parechovirus, bocavirus,
Mycoplasma pneumoniae,Chlamydia pneumoniae,S. aureus,
S. pneumoniae, and H. inﬂuenzae type B. Streptococcus
pneumoniae-positive specimens were serotyped bymultiplex
RT-PCR that detects 29 different serotypes. A centralized,
blinded PCR respiratory quality control panel was provided to
all sites to ensure procedure validation on-site before speci-
mens were processed locally.
Statistical methods. Qualitative variables were de-
scribed as numbers and percentages with comparison by
χ2 test, if appropriate, or Fischer’s exact test. Quantitative
variables were reported as median and interquartile
range (IQR) and compared by the Mann–Whitney U test or
Kruskal–Wallisone-wayanalysisof variance.Positive likelihood
(LR+) and negative likelihood (LR_) ratios of various clinical
signs and symptoms were calculated to detect hypoxemic
cases with the following formulae: LR+ = sensitivity/(1 _
speciﬁcity) and LR_= (1 _ sensitivity)/speciﬁcity. It has been
underlined that LR calculation is useful to improve di-
agnostic accuracy.16 LR could thus express the proportion
of hypoxemic children who presented a particular sign or
symptom divided by the proportion of non-hypoxemic
children with the same result.
Microbiological ﬁndings from different sample sites asso-
ciated with hypoxemia were assessed by logistic regression
modeling.Multivariate analysiswasperformed after univariate
analysis, with forced adjustment on patient age, time per
quarter, and study center. Microorganisms with P < 0.15 val-
ues on univariate analysis were initially entered in the multi-
variate model. Thus, backward stepwise deletion was applied
until all P values were < 0.05. Models were compared byWald
testing.
Factors associated with in-hospital mortality were
assessed with Kaplan–Meier curves and compared by
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log-rank test. Follow-up was censored at 14 days after ad-
mission or discharge, if duration of hospitalization was less
than 14 days. The characteristics of patients deceased
within 2 weeks (N = 13) were compared with non-deceased
patients (N = 392). Univariate and bivariate proportional
hazard Cox regression analyses were undertaken. No mul-
tivariateCoxmodel was ﬁtted owing to the limited number of
events. Bivariate analyses expressed the effect of onemajor
risk factor from univariate analysis adjusted on one other
possible confounder (age category, human immunodeﬁ-
ciency virus [HIV] seropositivity, time per quarter, or weight-
for-height Z score). All tests were two tailed, and P < 0.05
was considered signiﬁcant. Statistical analysis was con-
ducted with Stata version 13.0 (StataCorp., College Sta-
tion, TX).
Ethics. The study protocol, informed consent statement,
clinical research form, amendments, and all other study doc-
uments were submitted to and approved by the institutional
research ethics committee of each site.
RESULTS
Population description. Overall, 405 children with pneu-
monia, accounting for 3,338 hospitalization days, were in-
cluded. Among them, 235 (58.0%) were male. Median age
was 14 months (IQR = 8–27 months). Ninety-six (23.7%)
patients came from Lucknow, India, 71 (17.5%) were from
Vadu, India, 26 (6.4%) were fromAntananarivo,Madagascar,
114 (28.1%) from Bamako, Mali, and 98 (24.2%) from San
Lorenzo, Paraguay. The study periods at each site were
August 7, 2012, to December 6, 2013, in Lucknow; June 23,
2012, to March 5, 2014, in Vadu; February 4, 2011, to De-
cember 13, 2012, in Antananarivo; July 4, 2011, to November
14, 2012, in Bamako; and May 18, 2010, to May 20, 2013, in
San Lorenzo.
Patients differed between sites according to median
weight-for-height Z score (P = 0.001) and age category (P =
0.007), but did not differ between sites according to HIV se-
ropositivity (P = 0.33) and mortality (P = 0.37). Seventy pa-
tients were hypoxemic at admission. Global prevalence of
hypoxemia was 17.3% (95% conﬁdence interval [CI] =
13.9–21.3%).Median SO2was 95% (IQR= 92–97%), without
differences between countries (from 95% [IQR = 87–96%] in
Mali to 96% [IQR = 89–98%] in Vadu, India, P = 0.14). Table 1
compares the characteristics of hypoxemic and non-
hypoxemic patients.
HIV prevalence was 1.0% (N = 3). Median weight-for-height
Z score was _1.1 (IQR = _2.4; +0.1). Median length of hospital
stay was 7 days (IQR = 4–10 days). Median CRP level at ad-
mission was 24 mg/L (IQR = 6–90 mg/L), median white blood
cell count was 12,600 × 109 cells/L (IQR = 1,000–25,000 ×
109 cells/L), andmedianneutrophil proportionwas47%(IQR=
28–64%). Median PCT level at admission was 1.9 ng/mL
(IQR = 0.3–8.1 ng/mL), with mean of 15.6 ng/mL (minimum:
0.05, maximum: 585.5 ng/mL).
Overall, 70.5% tested positive for urinary antibiotics at ad-
mission. Among the 402 (99.3%) patients given antibiotics
during hospitalization for a median duration of 7 days (IQR =
5–10 days), 298 (74.5%) received monotherapy, with some
also getting multiple antibiotic lines. The main drugs
were ceftriaxone (N = 135, 26.0%), amoxicillin (N = 120,
23.1%), ampicillin (N = 51, 9.8%), amoxicillin/sulbactam
(N = 36, 6.9%), amoxicillin/clavulanic acid (N = 35, 6.7%),
oxacillin (N = 35, 6.7%), and vancomycin (N = 22, 4.2%).
Microbiological agents associated with hypoxemia in
children with pneumonia. Hypoxemic (N = 70) and non-
hypoxemic (N = 335) pneumonia cases did not differ by
median number of bacteria (1 versus 1, respectively,P= 0.85)
or viruses detected (1 versus 1, respectively, P = 0.72) in
nasal swabs/aspirates. Infection types (bacterial/viral/mixed)
did not differ in hypoxemic and non-hypoxemic patients
(P = 0.96). Table 2 reports themicrobiological agents linked
with hypoxemia. Univariate analysis disclosed that hMPV
and RSV detection in nasal samples was associated with
increased risk of hypoxemia (P = 0.04 and 0.008, re-
spectively). After adjustment on age, center, and calendar
time, microorganisms independently associated with
heightened risk of hypoxemia were hMPV (adjusted odds
ratio [aOR] = 2.5, 95% CI = 1.1–5.3) and RSV (aOR = 2.4,
95% CI = 1.0–5.8). Median SO2 was lower in RSV- and
hMPV-positive patients than in -negative patients but not
different between RSV- and hMPV-positive patients
(Figure 1). Pneumococcus serotypes 6AB and 10A from
respiratory samples were more frequent in hypoxemic than
in non-hypoxemic patients (22.9% versus 9.5%, re-
spectively, P = 0.002; 7.1% versus 1.5%, respectively, P =
0.006). The distribution of other serotypes was not signif-
icantly different in hypoxemic and non-hypoxemic children
(Supplemental Figure 1).
Clinical and para-clinical presentation in children with
hypoxemic pneumonia. Hypoxemic patients differed from
non-hypoxemic patients according to age (P = 0.02), history
of common cold/pharyngitis (P < 0.001), receipt of one dose
of pentavalent vaccine (P< 0.001), breathing rate (P= 0.009),
blood pressure (P < 0.01), chest indrawing (P = 0.02), cya-
nosis (P = 0.003), conjunctivitis (P = 0.01), rasping (P = 0.03),
radiological presentation (P = 0.009), mean white blood cell
count (P < 0.001), and PCT (P< 0.001) at admission (Table 1).
LR+ of lower chest indrawing was 2.3 (95% CI = 1.1–4.9),
and LR- was 0.9 (95% CI = 0.8–0.95). LR+ of cyanosis was
2.4 (95%CI = 1.4–4.1) and LR_ was 0.7 (95%CI = 0.5–0.99).
Other signs and symptoms were less predictive of hypox-
emia (data not shown). Hypoxemic patients differed from
non-hypoxemic patients in mean white blood cell count (P =
0.001) and PCT at admission (P = 0.03) but not regarding
CRP level.
Factors associatedwith death. Fourteen (3.5%) patients
died during hospital stay. Among them, 13 died within
14 days after hospital admission. The mortality rate was
8.6% in hypoxemic and 2.4% in non-hypoxemic patients
(P = 0.01). Eight deceased patients were not hypoxemic at
admission. Among them, the causes of death were multiple
organ dysfunction syndrome (N = 4), acute respiratory
distress syndrome with septic shock (N = 2), severe pneu-
monia in HIV (N = 1), and cardiac arrest (N = 1).
Table 3 reports the microbiological, clinical, and para-
clinical ﬁndings associated with death on univariate Cox
analysis. Streptococcus pneumoniae detection by blood
PCR, hypoxemia, and PCT ³ 50 ng/mL at admission were
associated with increased risk of death (log-rank test: P =
0.003, P = 0.002, and P < 0.0001, respectively, Figure 2A–C).
Other characteristics or microorganisms, including S.
pneumoniae in respiratory samples, were not signiﬁcantly
associated with death (Supplemental Tables 1 and 2). No
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TABLE 1
Description of hypoxemic and non-hypoxemic pneumonia cases (N = 405)
Characteristics at admission Hypoxemic* pneumonia (N = 70) Non-hypoxemic* pneumonia (N = 335) P
Demographics
Gender, male 38/70 (54.3)† 197/335 (58.8)† 0.49
Age, months, median (IQR) 12 (4–23) 15 (8–30) 0.02
Age category 0.13
2–11 months 32/70 (45.7) 132/335 (39.4)
12–23 months 21/70 (30.0) 80/335 (23.9)
24–60 months 17/70 (24.3) 123/335 (36.7)
Weight-for-height Z score, median (IQR) _1.4 (_2.9; 0) _1.1 (_2.1; 0.3) 0.20
Weight-for-height Z score £ 2 SD 27/67 (40.3) 65/233 (27.9) 0.05
Weight-for-height Z score £ 3 SD 14/67 (20.9) 31/233 (13.3) 0.12
Delay from onset, days, median (IQR) 6 (3–7) 5 (3.5–7) 0.07
Medical history
Heart disease 6/69 (8.7) 21/335 (6.3) 0.46
Lung disease 4/67 (6.0) 32/335 (9.5) 0.35
Asthma 0/69 (0) 3/335 (0.9) 0.43
HIV positive 1/61 (1.6) 2/239 (0.8) 0.57
Contracted common cold/pharyngitis‡ 34/69 (49.3) 86/330 (26.1) < 0.001
Previous tuberculosis 0/68 (0) 2/335 (0.6) 0.52
Contact with a tuberculosis case 0/68 (0) 1/298 (0.3) 0.63
Prior treatment of fever 44/70 (62.9) 255/335 (76.1) 0.02
Pneumococcal conjugate vaccine 2/54 (3.7) 15/297 (5.0) 0.67
DPT-HepB-Hib vaccine, one dose 59/67 (88.1) 191/303 (63.0) < 0.001
DPT-HepB-Hib vaccine, three doses 45/65 (69.2) 156/291 (53.6) 0.02
Vital signs at admission
Temperature, C, median (IQR) 38.4 (37.5–39) 38.3 (37.8–38.8) 0.50
Breathing rate, cycles/minute, median (IQR) 58 (54–68) 56 (49–64) 0.009
Cardiac rate, cycles/minute, median (IQR) 151 (136–167) 140 (123–156) 0.001
Systolic pressure, mmHg, median (IQR) 90 (80–92) 92 (88–100) 0.007
Diastolic pressure, mmHg, median (IQR) 60 (50–61) 66 (60–70) 0.002
SO2, %, median (IQR) 85 (80–87) 96 (94–97) < 0.001
Clinical signs/symptoms at admission
Dyspnea 67/70 (95.7) 324/335 (96.7) 0.68
Lower chest indrawing 63/70 (90.0) 257/333 (77.2) 0.02
Cough 67/68 (98.5) 330/335 (98.5) 0.99
Pulmonary crackles 62/70 (88.6) 301/334 (90.1) 0.70
Rhonchi 14/62 (22.6) 38/245 (15.5) 0.18
Wheezing 5/70 (7.1) 50/332 (15.1) 0.08
Rhinopharyngitis 11/69 (15.9) 61/334 (18.3) 0.65
Prostration or lethargy 29/69 (42.0) 109/335 (32.5) 0.13
Inability to drink 14/69 (20.3) 54/334 (16.2) 0.40
Diarrhea 4/70 (5.7) 44/335 (13.1) 0.08
Cyanosis 10/70 (14.3) 16/333 (4.8) 0.003
Vomiting 7/69 (10.1) 49/334 (14.7) 0.32
Convulsions 3/69 (4.3) 13/335 (3.9) 0.86
Conjunctivitis 4/69 (5.8) 4/335 (1.2) 0.01
Diminished breathing sounds 25/61 (41.0) 90/244 (36.9) 0.55
Dullness to percussion 18/70 (25.7) 84/332 (25.3) 0.94
Otitis 0/70 (0) 3/334 (0.9) 0.43
Rasping 4/62 (6.4) 42/245 (17.1) 0.03
Radiology
Generalized, dense, homogenous
opaciﬁcation
30/69 (43.5) 92/334 (27.5) 0.009
Other ﬁndings 39/69 (56.5) 242/334 (72.5)
Pleural effusion 5 (7.3) 78 (23.4) 0.003
Biology at admission
White blood cell count, ×109 cells/L, median
(IQR)
22 (8.9–29.1) 11.5 (1–23.9) < 0.001
White blood cell count > 20 × 109 cells/L 37/67 (55.2) 71/235 (30.2) < 0.001
Neutrophils, %, median (IQR) 47 (27–68) 45 (28–64) 0.70
C reactive protein, mg/L, median (IQR) 18 (8–63) 24 (6–94) 0.58
Procalcitonin, ng/mL, median (IQR) 4.3 (0.4–16.2) 1.6 (0.2–6.6) 0.03
Procalcitonin > 50 ng/mL 10/62 (16.3) 16/306 (5.2) 0.002
Positive antibiotic urinary test 35/42 (83.3) 187/210 (89.0) 0.30
During hospital stay
Oxygen 64/69 (92.7) 196/333 (58.9) < 0.001
Oxygen duration, days, median (IQR) 2 (1–3) 2 (1–3) 0.39
Antibiotics 62/63 (98.4) 295/296 (99.7) 0.23
Antibiotics duration, days, median (IQR) 6 (4–8) 7 (5–10) 0.02
Other therapy 64/68 (94.1) 220/317 (69.4) < 0.001
Hospitalization length, days, median (IQR) 5.5 (4–9) 7 (4–11) 0.03
(continued)
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S. pneumoniae serotype was signiﬁcantly associated with
higher mortality (data not shown). Streptococcus pneu-
moniae detection by blood PCR, hypoxemia and PCT ³ 50
ng/mL at admission were linked with augmented proba-
bility of death on univariate survival analysis (crude hazard
ratio [cHR] = 4.6, 95% CI = 1.5–14.0; cHR = 4.8, 95% CI =
1.6–14.4; cHR = 22.4, 95% CI = 7.3–68.5, respectively).
These associations were consistent on bivariate Cox re-
gression with adjustment on country, age category, HIV
seropositivity, time (per quarter), or weight-for-height
Z score (Supplemental Figure 2). In addition, S. pneumoniae
detection by blood PCR was associated with increased
risk of death (aOR = 4.0, 95% CI = 1.3–12.4), in-
dependently of hypoxemia at admission (aOR = 4.3, 95%
CI = 1.4–12.8).
DISCUSSION
One of the objectives of this study was to assess mi-
crobiological agents and other predictors of hypoxemia
and death in under 5-year-old hospitalized children with
pneumonia from developing countries. We observed that
two viruses, namely RSV and hMPV, detected in re-
spiratory samples by PCR, were independently associated
with increased risk of hypoxemia, while no bacterial agent
was signiﬁcantly linked with it. On the other hand,
S. pneumoniae detection by blood PCR was associated
with a higher rate of in-hospital mortality in the study
population independently of hypoxemia at admission.
Several predictors of hypoxemic pneumonia were identi-
ﬁed. However, none had high likelihood ratio. Elevated PCT
concentration and hypoxemia were straightforward pre-
dictors of death in children with pneumonia. The contri-
bution of hypoxemia to the risk of death was independent
of pneumococcus detection by blood PCR.
Several studies have investigated factors associatedwith
hypoxemia, particularly clinical predictors.6–8,17 However,
few of them have researched the links between microbio-
logical ﬁndings and severity in different developing coun-
tries, with a standardized protocol. We observed that
TABLE 1
Continued
Characteristics at admission Hypoxemic* pneumonia (N = 70) Non-hypoxemic* pneumonia (N = 335) P
Recovery 58/68 (85.3)† 314/334 (94.0)† 0.01
Death 6/70 (8.6) 8/335 (2.4) 0.01
Transfer 3/69 (4.3) 4/335 (1.2) 0.07
DPT-HepB-Hib = diphtheria, pertussis, tetanus, hepatitis B, and Haemophilus inﬂuenzae type b; HIV = human immunodeﬁciency virus; IQR = interquartile range; SD = standard deviation;
ILI = inﬂuenza-like illness; SO2 = oxygen saturation.
* SO2 lower than 90%.
† Expressed as number/number with available data (%), unless speciﬁed otherwise.
‡Within 2 weeks.
TABLE 2
Microbiological agents associated with hypoxemia in children with pneumonia (N = 405)
Microbiological agent Hypoxemic* pneumonia (N = 70) Non-hypoxemic* pneumonia (N = 335) P Crude odds ratio (95% CI) Adjusted odds ratio† (95% CI)
Respiratory sampling
Streptococcus pneumoniae 44/70 (62.9)‡ 202/335 (60.3)‡ 0.69 1.1 (0.7–1.9) –
Staphylococcus aureus 12/69 (17.4) 58/335 (17.3) 0.99 1.0 (0.5–2.0) –
Haemophilus inﬂuenzae 4/70 (5.7) 17/335 (5.1) 0.83 1.1 (0.4–3.5) –
Mycoplasma pneumoniae 0/70 (0) 3/335 (0.9) 0.43 NE –
Chlamydia spp. 0/70 (0) 1/335 (0.4) 0.65 NE –
hMPV 10/70 (14.3) 23/335 (6.9) 0.04 2.3 (1.0–5.0) 2.4 (1.0–5.8)
Coronavirus 63 1/70 (1.4) 1/335 (0.3) 0.22 4.8 (0.3–78.3) –
Coronavirus 229 1/70 (1.4) 3/335 (0.9) 0.68 1.6 (0.2–15.6) –
Coronavirus 43 1/70 (1.4) 14/335 (4.2) 0.27 0.3 (0.04–2.6) –
HKU 2/70 (2.9) 9/335 (2.7) 0.94 1.1 (0.2–5.0) –
Adenovirus 4/70 (5.7) 23/335 (7.8) 0.55 0.7 (0.2–2.1) –
Enterovirus 4/70 (5.7) 22/335 (6.6) 0.79 0.9 (0.3–2.6) –
Parechovirus 1/37 (2.7) 1/254 (0.11) 0.11 4.8 (0.3–78.3) –
Rhinovirus 17/70 (24.3) 97/335 (29.0) 0.43 0.8 (0.4–1.4) –
RSV 18/70 (25.7) 44/335 (13.1) 0.008 2.3 (1.2–4.3) 2.5 (1.1–5.3)
hPIV 1 3/70 (4.3) 13/335 (3.9) 0.87 1.1 (0.3–4.0) –
hPIV 2 1/70 (1.4) 1/335 (0.3) 0.22 4.8 (0.3–78.3) –
hPIV 3 1/70 (1.4) 21/335 (6.3) 0.10 0.2 (0.03–1.6) –
hPIV 4 2/70 (2.9) 10/335 (3.0) 0.95 1.0 (0.2–4.5) –
Inﬂuenza virus A 4/70 (5.7) 24/335 (7.2) 0.66 0.8 (0.3–2.3) –
Inﬂuenza virus B 0/70 (0) 8/335 (2.4) 0.19 NE –
Inﬂuenza virus A H1/N1 2/70 (2.9) 9/335 (2.7) 0.94 1.1 (0.2–5.0) –
Bocavirus 3/70 (4.3) 23/335 (6.9) 0.42 0.6 (0.2–2.1) –
Blood sample
Streptococcus pneumoniae 10/70 (14.3) 41/335 (12.2) 0.64 1.2 (0.6–2.5) –
Staphylococcus aureus 3/70 (4.3) 5/335 (1.5) 0.13 3.0 (0.7–12.7) –
Haemophilus inﬂuenzae 3/70 (4.3) 15/335 (4.5) 0.94 1.0 (0.3–3.4) –
CI = conﬁdence interval; hMPV = human metapneumovirus; hPIV = human parainﬂuenza virus; NE = non-estimable; RSV = respiratory syncytial virus.
* SO2 lower than 90%.
† After multivariate logistic regression, adjusted on other microorganisms signiﬁcantly associated with hypoxemia, patient age, time period per quarter and center.
‡ Data are expressed as number positive/number with available data with % unless speciﬁed otherwise.
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two viruses were associated with increased risk of hypox-
emia. Viral pneumonia induced diffuse, bilateral, pulmonary
damage,18 compared with bacterial pneumonia, with more
frequent, well-systematized alveolar localization.19 This is
probably the reason why we noted that the two viral etio-
logical agents evoking pneumonia were associated with
hypoxemia.
RSV is the leading cause of viral pneumonia in children,20
frequently in association with severe disease.21 We observed
that it might be also a major cause of hypoxemic pneumonia.
On the other hand, RSVdetectionwas not related to increased
mortality, but it is estimated that 66,000–199,000 children
could die of RSV-associated pneumonia worldwide every
year. Our study’s power was probably too limited to demon-
strate such associations.
However, with prevalence of exposure in non-hypoxemic
patients ranging from 10% to 50%, with bilateral tests and
α < 0.05, study power was ³ 80% to detect OR ³ 2.5. Similar
results have been reported recently in a study from
Botswana,22 where researchers noted that RSV pneumonia
in children inducedmore complications and longer duration
of hospitalization, but mortality was lower in comparison to
other agents. hMPV is recognized as a frequent etiological
agent of pneumonia, causing severe disease.23 Here, we
determined that detection of this virus was associated with
hypoxemic pneumonia in children. These ﬁndings might be
related to the fact that these two viruses in respiratory
samples might be the etiological agents of pneumonia.
Another hypothesis is that they might be associated with
co-infections. However, we did not discern any relationship
between infection type (bacterial, viral, or coinfection) and
the risk of hypoxemia.
The main clinical predictors of hypoxemic pneumonia
were lower chest indrawing and cyanosis with LR+ ratios
between 2 and 3. If these signs are present, hypoxemia
must be suspected in the absence of pulse oximetry, and
oxygen therapy should be initiated promptly. Nevertheless,
we did not discern that one sign had a high LR+ ratio,
conﬁrming that pulse oximetry is important for initial eval-
uation of pneumonia severity and should be implemented
more widely in developing countries.4 Lower chest
indrawing has been reported to be predictive of hypoxemia
in children from Nigeria,8 while breathing rate ³ 60
cycles/minute has been encountered with hypoxemia in
children from Papua New Guinea.24 Other predictors are
less known. The designation and validation of a simple,
robust score predicting hypoxemia might be useful in
resource-limited settings.
Streptococcus pneumoniae is recognized as the main
etiological agent of severe pneumonia and death from pneu-
monia in children.25 The diagnosis of pneumococcus pneu-
monia is, however, difﬁcult at the individual level, because of
the low sensitivity of blood culture, particularly in case of
previous exposure to antibiotics. In addition, the clinical
meaning of pneumococcus detection in nasal samples by
molecular testing is difﬁcult to interpret because of the high
prevalence of S. pneumoniae respiratory carriage in asymp-
tomatic children.26 We did not observe associations between
pneumococcus detection in nasal samples and disease se-
verity, althoughpneumococcus-positive bloodPCRwas linked
with greater mortality. Molecular S. pneumoniae detection by
blood PCR is thus helpful in identifying bacterial pneumonia
cases with the poorest prognosis who might need intensive
therapies. Interpretationofmolecularmethods, suchasPCR, to
TABLE 3
Factors associated with death of pneumonia in children within 2 weeks after hospital admission
Characteristics at admission Deceased (N = 13) Alive (N = 392) P Crude hazard ratio (95% CI)
Streptococcus pneumoniae, PCR blood 5/13 (38.5)* 46/392 (11.7)* 0.01 4.6 (1.5–14.0)
hPIV 2, nasal swab/aspirate 1/13 (7.7) 1/392 (0.3) 0.06 23.6 (3.0–183.9)
Hypoxemia 6/13 (46.1) 64/392 (16.3) 0.01 4.8 (1.6–14.4)
HIV positive 1/10 (10.0) 2/290 (0.7) 0.10 9.6 (1.2–75.9)
Weight-for-height Z score, median (IQR) _2.1 (_4.3, _0.6) _1.1 (_2.3, _0.1) 0.05 1.01 (0.99–1.04)
Weight-for-height Z score £ 3 SD 4/11 (36.4) 41/289 (14.2) 0.06 2.8 (0.8–9.5)
Inability to drink 5/13 (38.5) 63/390 (16.1) 0.05 2.7 (0.9–8.4)
Procalcitonin, ng/mL, median (IQR) 71.5 (8.3–111.5) 1.6 (0.3–6.6) < 0.001 1.11 (1.07–1.15)†
Procalcitonin ³ 50 ng/mL 8/13 (61.5) 18/355 (5.1) < 0.001 22.4 (7.3–68.5)
Oxygen saturation, %, median (IQR) 91 (86–96) 95 (92–97) 0.04 2.1 (1.3–3.5)‡
CI = conﬁdence interval; HIV = human immunodeﬁciency virus; hPIV = human parainﬂuenza virus; IQR = interquartile range; SD = standard deviation.
* Expressed as number/number with available data (%) unless speciﬁed otherwise.
† Per 10 ng/mL increase.
‡ Per 10% decrease.
FIGURE 1. Oxygen saturation (SO2) in children with RSV or hMPV
pneumonia,N = 404. Mean SO2was 93.9% (+5.0) in hMPV- and RSV-
negative patients (N = 311), 90.7% (+8.1) in hMPV-positive patients
(N = 32), and 90.4% (+8.5) in RSV-positive patients (N = 61). One
patient coinfected by hMPVandRSVwas excluded from this analysis:
his SO2 was 96%. SO2 between groups was compared by Student’s t
test. hMPV = human metapneumovirus; neg. = negative; RSV = re-
spiratory syncytial virus; pos. = positive.
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identify the etiology of pneumonia in children is, however,
challenging. Respiratory viruses can be identiﬁed in asymp-
tomatic children, and secondary bacterial infections in the
lungs can easily be missed by these methods. In addition,
identiﬁcation of S. pneumoniae in blood by highly sensitive
PCR may detect children with nasopharyngeal coloni-
zation only, which could lead to potential misclassiﬁcation
bias, particularly when using results of nasopharyngeal speci-
mens to determine the etiology of pneumonia in children. We
mustbecautiouswith results interpretation.Moreover, PCTwas
the major biomarker associated with in-hospital death in our
cohort. Several studies previously found an association be-
tween PCT and the risk of death or bacterial disease.27–30
However, such linkage has rarely been seen in pneumonia-
infected children living in developing countries.
The main strength of the present study is the prospective
data collection on a standardized form at different sites,
with advanced molecular diagnosis in all cases, which re-
inforces internal validity. Its main limitations include paucity
of information on exposures before hospital admission (i.e.,
breastfeeding, food intake, or vitamin supplementation). In
addition, microbiological diagnosis of pneumonia is difﬁcult
because sensitive and speciﬁc tests are not routinely
available in practice. Thus, based on respiratory samples,
we were unable to differentiate colonization from infection,
particularly by S. pneumoniae.31 However, analysis of the
relationship between results from different samples and
severity was contributive: we did not ﬁnd associations be-
tween nasal colonization by pneumococcus and disease
severity, hypoxemia, or death. Finally, selection bias might
have occurred because of patient recruitment in hospital
with inclusion of more severe cases or patients with easier
access to care. However, we did not discern signiﬁcant
heterogeneity regarding SO2 of infants at admission and in-
hospital mortality, which suggests that the results might be
generalizable to different settings. We must acknowledge
that 41% of the study population was enrolled in two sites
from India, which might limit external validity. This pro-
portion is, however, in accordance with estimates of global
pneumonia incidence and related mortality: India might
have accounted for almost 30% of the total number of se-
vere pneumonia cases in children and 40%of the number of
deaths worldwide.25
In conclusion, RSV and hMPV could be major causes of
hypoxemia in children with severe pneumonia in developing
countries, while S. pneumoniae detection by blood PCR is
predictive of high risk of in-hospital mortality. Viral etiology
might be considered in hypoxemic patients, whereas in very
severe pneumonia, which can lead to death, S. pneumoniae
may be implicated as the primary cause, even in the ab-
sence of hypoxemia at admission. Tachypnea and lower
chest indrawing could be useful indicators of possible
hypoxemia requiring oxygen therapy. Pulse oximetry
should be included for better diagnosis in developing
countries. Given these ﬁndings, preventive measures, such
as increased vaccination coverage of children in developing
countries, oxygen therapy of hypoxemic patients, and inten-
sive cardiovascular support, even in non-hypoxemic patients,
would reduce the burden of death by pneumonia in children.
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